Science Explorer Back to mapMap

Most cited papers from Esperion Therapeutics (United States)

What are the most cited papers from Esperion Therapeutics (United States)?

The most cited paper from Esperion Therapeutics (United States) is "Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients" (Steven E. Nissen et al., 2023), with 951 citations. Next come "Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol" (815) and "Aromaticity as a Cornerstone of Heterocyclic Chemistry" (812).

Showing 50 of 60 papers. Every paper with more than 52 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients Steven E. Nissen et al. · New England Journal of Medicine Open access 4 Mar 2023 951
2 Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol Kausik Kumar Ray, Harold Edward Bays, Alberico Luigi Catapano et al. · New England Journal of Medicine Open access 13 Mar 2019 815
3 Aromaticity as a Cornerstone of Heterocyclic Chemistry Alexandrù T. Balaban, Daniela Carmen Oniciu, ALAN ROY KATRITZKY · Chemical Reviews Review 17 Apr 2004 812
4 Methionine‐deficient diet extends mouse lifespan, slows immune and lens aging, alters glucose, T4, IGF‐I and insulin levels, and increases hepatocyte MIF levels and stress resistance Richard A. Miller, Gretchen Buehner, Yayi Chang et al. · Aging Cell Open access 13 Apr 2005 755
5 Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis Stephen L. Pinkosky, Roger S. Newton, Emily Anne Day et al. · Nature Communications Open access 28 Nov 2016 498
6 Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease Anne Carol Goldberg, Lawrence A. Leiter, Erik S.G. Stroes et al. · JAMA Open access 12 Nov 2019 486
7 Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance Ulrich Laufs, Maciej Banach, G.B. John Mancini et al. · Journal of the American Heart Association Open access 29 Mar 2019 443
8 Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study Christie Mitchell Ballantyne, Maciej Banach, G.B. John Mancini et al. · Atherosclerosis Open access 12 Jun 2018 430
9 Lipogenesis inhibitors: therapeutic opportunities and challenges Battsetseg Batchuluun, Stephen L. Pinkosky, Gregory R. Steinberg · Nature Reviews Drug Discovery ReviewOpen access 14 Jan 2022 407
10 Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy Christie Mitchell Ballantyne, Ulrich Laufs, Kausik Kumar Ray et al. · European Journal of Preventive Cardiology Open access 29 Jul 2019 367
11 Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction Maria-Corina Șerban, Lisandro Damián Colantonio, Angelika D. Manthripragada et al. · Journal of the American College of Cardiology Open access Mar 2017 321
12 Cardiovascular Status of Carriers of the Apolipoprotein A-I Milano Mutant Cesare Riccardo Sirtori, Laura Calabresi, Guido Franceschini et al. · Circulation Open access 17 Apr 2001 320
13 Quantitative Measures of Aromaticity for Mono-, Bi-, and Tricyclic Penta- and Hexaatomic Heteroaromatic Ring Systems and Their Interrelationships ALAN ROY KATRITZKY, Karl Jug, Daniela Carmen Oniciu · Chemical Reviews Review 20 Apr 2001 306
14 AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases Rai Ajit K. Srivastava, Stephen L. Pinkosky, Sergey Ivanovich Filippov et al. · Journal of Lipid Research Open access 14 Jul 2012 299
15 Metabolomics applications of FT‐ICR mass spectrometry Stephen C. Brown, Gary H. Kruppa, Jean‐Louis Dasseux · Mass Spectrometry Reviews 30 Mar 2004 285
16 AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism Stephen L. Pinkosky, Sergey Ivanovich Filippov, Rai Ajit K. Srivastava et al. · Journal of Lipid Research Open access 3 Nov 2012 241
17 NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity Per Albertsson, Per H. Basse, Marianne Hokland et al. · Trends in Immunology Review 11 Oct 2003 226
18 Increased Atherosclerosis in ApoE and LDL Receptor Gene Knock-Out Mice as a Result of Human Cholesteryl Ester Transfer Protein Transgene Expression Andrew S. Plump, Lori Masucci-Magoulas, Can Bruce et al. · Arteriosclerosis Thrombosis and Vascular Biology Apr 1999 224
19 Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia Marisa R. Morrow et al. · Cell Metabolism Open access Jun 2022 196
20 Recombinant Apolipoprotein A-I Milano Infusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks Giulia Chiesa, Elena Monteggia, Marta Marchesi et al. · Circulation Research Open access 17 May 2002 196
21 Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia Maciej Banach, Paul Barton Duell, Antonio M. Gotto et al. · JAMA Cardiology Open access Jul 2020 193
22 Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia Christie Mitchell Ballantyne, Michael H. Davidson, Diane Elaine MacDougall et al. · Journal of the American College of Cardiology Open access 13 Jun 2013 179
23 Mouse Macrophage Paraoxonase 2 Activity Is Increased Whereas Cellular Paraoxonase 3 Activity Is Decreased Under Oxidative Stress Mira Rosenblat, Dragomir Ivanov Draganov, Catherine E. Watson et al. · Arteriosclerosis Thrombosis and Vascular Biology Mar 2003 167
24 Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance Paul D. Thompson, John Rubino, Matthew James Janik et al. · Journal of clinical lipidology Open access 29 Mar 2015 165
25 Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance Paul Daniel Thompson, Diane Elaine MacDougall, Roger S. Newton et al. · Journal of clinical lipidology Open access 6 Jan 2016 147
26 Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients Steven E. Nissen, Venu Menon, Stephen James Nicholls et al. · JAMA Open access 24 Jun 2023 145
27 Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance Paul M. Ridker, Lei Lei, Michael J. Louie et al. · Circulation Open access 6 Nov 2023 144
28 Evidence that MIG-6 is a tumor-suppressor gene Y-W Zhang, Ben Staal, Yingchun Su et al. · Oncogene 3 Jul 2006 142
29 Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance StephenJ Nicholls, A. Michael Lincoff, Harold Edward Bays et al. · American Heart Journal Open access 23 Oct 2020 139
30 Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults Martin Markowitz, Andrew R. Zolopa, K. Squires et al. · Journal of Antimicrobial Chemotherapy 6 Feb 2014 129
31 Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy Christie Mitchell Ballantyne, James M. McKenney, Diane Elaine MacDougall et al. · The American Journal of Cardiology Open access 6 Apr 2016 128
32 T Cell Responses in Mammalian Diaphanous-related Formin mDia1 Knock-out Mice Kathryn M. Eisenmann, Richard A. West, Dagmar Hildebrand et al. · Journal of Biological Chemistry Open access 27 Jun 2007 123
33 Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders Stephen L. Pinkosky, Pieter H.E. Groot, Narendra D. Lalwani et al. · Trends in Molecular Medicine Review 12 Oct 2017 119
34 Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins Shucun Qin, Koichi Kawano, Can Bruce et al. · Journal of Lipid Research Open access Feb 2000 111
35 Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials Harold Edward Bays, Maciej Banach, Alberico Luigi Catapano et al. · Journal of clinical lipidology Open access Sep 2020 105
36 Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr −/− Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid Joshua P Samsoondar, Amy C. Burke, Brian G. Sutherland et al. · Arteriosclerosis Thrombosis and Vascular Biology Open access 3 Feb 2017 98
37 Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer José Baselga, Alexey Manikhas, Javier Cortés et al. · Annals of Oncology Open access 9 Jan 2014 98
38 Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial Kausik Kumar Ray, Stephen James Nicholls, Na Li et al. · The Lancet Diabetes & Endocrinology Open access 4 Dec 2023 97
39 Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice Rai Ajit K. Srivastava, Ravi Jahagirdar, Salman Azhar et al. · Molecular and Cellular Biochemistry 13 Feb 2006 97
40 Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial John Rubino, Diane Elaine MacDougall, Lulu Ren Sterling et al. · Atherosclerosis 30 Dec 2020 95
41 Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease Yu-Wen Zhang, Yanli Su, Nathan James Lanning et al. · Proceedings of the National Academy of Sciences Open access 8 Aug 2005 95
42 Evidence-based goals in LDL-C reduction Handrean Soran, Ricardo E. Dent, Paul N. Durrington · Clinical Research in Cardiology Open access 25 Jan 2017 93
43 Myeloproliferative Defects following Targeting of the Drf1 Gene Encoding the Mammalian Diaphanous–Related Formin mDia1 Jun Peng, Susan M. Kitchen, Richard A. West et al. · Cancer Research 15 Aug 2007 92
44 ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK Sergey Ivanovich Filippov, Stephen L. Pinkosky, Richard J. Lister et al. · Journal of Lipid Research Open access 25 May 2013 92
45 Dose-Related Effects of Repeated ETC-216 (Recombinant Apolipoprotein A-IMilano/1-Palmitoyl-2-Oleoyl Phosphatidylcholine Complexes) Administrations on Rabbit Lipid-Rich Soft Plaques Cinzia Parolini, Marta Marchesi, Paolo Lorenzon et al. · Journal of the American College of Cardiology Open access Mar 2008 90
46 Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial Narendra D. Lalwani, Jeffrey Christian Hanselman, Diane Elaine MacDougall et al. · Journal of clinical lipidology 13 May 2019 79
47 Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome Clay T. Cramer, Brian D. Goetz, Krista L. Hopson et al. · Journal of Lipid Research Open access 8 Jun 2004 74
48 Intramural Delivery of Recombinant Apolipoprotein A-I Milano /Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries Sanjay Kaul, Vladimir Rukshin, Raul Santos et al. · Circulation 13 May 2003 74
49 Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial John Rubino, Diane Elaine MacDougall, Lulu Ren Sterling et al. · Journal of clinical lipidology Open access 28 May 2021 72
50 Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial Paul M. Ridker, Lei Lei, Kausik Kumar Ray et al. · Journal of clinical lipidology 14 Feb 2023 71

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.